SEC Filing Summary: Celsus Therapeutics Plc (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Celsus Therapeutics Plc (not Akari Therapeutics Plc) on September 15, 2015, covering events occurring on September 9, 2015. The registrant is incorporated in England and Wales and operates as a biopharmaceutical company.
Key Financial Metrics
This filing is a current report regarding a corporate action and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
- ADS Ratio Change: The company entered into Amendment No. 2 to its Depositary Agreement with Deutsche Bank Trust Company Americas.
- New Ratio: Each American Depositary Share (ADS) will now represent 100 Ordinary Shares.
- Effective Date: The change became effective on September 17, 2015.
Guidance, Outlook, and Risks
The filing contains no management commentary on financial outlook, guidance, or specific risk factors beyond the standard disclosure that the description of the Amendment is qualified by reference to the full text of the agreement filed as an exhibit.
Key Facts for Investor Verification
- Verify the impact of the new 1:100 ADS ratio on share price and liquidity.
- Confirm the effective date of September 17, 2015, for the ADS ratio change.
- Review the full text of Amendment No. 2 (Exhibit 10.1) for any additional terms or conditions not summarized in the 8-K.
- Note the discrepancy between the requested company name (Akari Therapeutics) and the actual registrant (Celsus Therapeutics).